Bacterial strains colonizing subcutaneous catheters of personal insulin pumps

• Autorzy: Nowakowska M , Jarosz-Chobot P. , Polanska J. , Machnica L.
• Języki publikacji: EN

Abstrakty

EN

Continuous subcutaneous insulin infusion (CSII) is a commonly used, safe intensive insulin therapy method effective in maintaining normoglycaemia. The disadvantage of CSII are skin infections of the catheter injection site. The aim of the study was to gain insight on the colonization of subcutaneous insulin pump catheters by skin flora and to investigate the correlation between Staphylococcus aureus carrier state (presence in the nose), its presence on the skin and catheter. 141 catheters obtained from 94 children with T1DM and CSII were examined using the semi quantitative culture technique of Maki. The result was positive in 34 examinations (24.1%) in 30 children (31.9%). Most often coagulase negative staphylococci were isolated (30), mainly Staphylococcus epidermidis, 1/3 of the staphylococci were methicillin resistant. S. aureus was detected in 7 examinations in 6 children. S. aureus carrier state was proved in 31.9% of all examined patients, more often in children with a positive catheter culture (41.4%), there were no MRSA. No correlation between S. aureus carrier state and catheter colonization was shown. Statistically significant correlations between: coagulase negative staphylococci presence, including the methicillin resistant strains, on the skin and on the catheter surface (p<0.0001); glycosylated hemoglobin (HbA1c) and bacteria catheter colonization (p = 0.0335) were observed. Subcutaneous catheter colonization by microorganisms often occurs in CSII. Microorganisms found on the skin are the most frequent cause of the subcutaneous catheter infection.

Słowa kluczowe

EN

personal insulin pump; diabetes mellitus; Staphylococcus aureus; Staphylococcus capitis; Corynebacterium jeikeium; human disease; catheter; catheter colonization; continuous subcutaneous insulin infusion; bacterial strain; intensive insulin therapy; Staphylococcus haemolyticus; skin infection; Staphylococcus epidermis

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2007
• Tom: 56
• Numer: 4
• Opis fizyczny: p.239-243,fig.,ref.

Twórcy

autor

Nowakowska M

• Medical University of Silesia, Medykow 16, 40-752 Katowice, Poland

autor

Jarosz-Chobot P.

autor

Polanska J.

autor

Machnica L.

Bibliografia

• Bruttomesso D., A. Pianta, D. Crazzolara, E. Scaldaferri, L. Lora, G. Guarneri, A. Mongillo, R. Gennaro, M. Miola, M. Moretti and others. 2002. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet. Med. 19: 628-634.
• Campos J.M., A.M. McNamara and B.J. Howard. 1994. Specimen collection and processing, pp. 213-242. In: Howard B.J, J.F. Reiser, T.F. Smith, A.S.Weissfeld, and R.C. Tilton (eds). Clinical and Pathogenic Microbiology. 2nd ed. St. Luis: Mosby-Year Book, Inc.
• Chantelau E., G. Lange, G.E. Sonnenberg and M. Berger. 1987. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment. Diabetes Care 10: 478-482.
• Chantelau E., M. Spraul, I. Muhlhauser, R. Gause and M. Berger. 1989. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 32: 421-426.
• Dudley S. and P.J. Hammond. 2002. Safety aspects of continuous subcutaneous insulin infusion (CSII). Diabet. Med. 19 (Suppl. 2): A50.
• Jarosz-Chobot P., M. Nowakowska and J. Polanska. 2007. Seeking the factors predisposing to local skin inflammatory state development in children with type 1 diabetes treated with continuous subcutaneous insulin infusion. Exp. Clin. Endocrinol. Diabetes 115: 179-181.
• Liebl A. and L. Krinelke. 2003. Long-term results of insulin pump therapy (CSII) in adolescents and adults with type 1 diabetes mellitus in Germany. Diabetol. Pol. 10: 179-185.
• Linkeschova R., M. Raoul, U. Bott, M. Berge and M. Spraul. 2002. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet. Med. 19: 746-751.
• Mecklenberg R.S., E.A. Benson, J.W. Benson, P.N. Fredlund, T. Guinn, R.J. Metz, R.L. Nielsen and C.A. Sannar. 1984. Acute complications associated with insulin infusion therapy. JAMA 252: 3265-3269.
• Renard E., T. Rostane, C. Carriere, H. Marchandin, D. Jacques-Apostol, D. Lauton, F. Gibert-Boulet and J. Bringer. 2001. Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. Diabetes Metab. 27: 62-65.
• Rolf R., A. Pfutzner, M. Trautmann, O. Harzer, K. Sauter and R. Landgraf. 1999. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 22: 784-788.
• Torrance T.,V. Franklin and S. Green. 2003. Insulin pumps. Arch. Dis. Child 88: 949-953.
• van Faassen I., P.P. Razenberg, A.M. Simoons-Smit and E.A. van der Veen. 1989. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy. Diabetes Care 12: 153-155.